From: COVID-19 pandemic crisis—a complete outline of SARS-CoV-2
Antiviral agents | Supporting agents | Others |
---|---|---|
• Baloxavir • Chloroquine phosphate • Favipiravir • HIV protease inhibitors • Hydroxychloroquine • Neuraminidase inhibitor • Remdesivir • Umifenovir | • Anakinra • Azithromycin • Baricitinib (Olumiant®) • Colchicine • Corticosteroids (general) • COVID-19 • Convalescent plasma • Epoprostenol (inhaled) • Methylprednisolone (DEPO-Medrol®, SOLU-Medrol®) • Nitric oxide (inhaled) • Ruxolitinib (Jakafi®) • Sarilumab (Kefzara®) • Siltuximab (Sylvant®) • Sirolimus (Rapamune®) • Tocilizumab (Actemra®) | • ACE inhibitors, angiotensin II receptor blockers (ARBs) • Anticoagulants (low molecular weight heparin [LMWH], unfractionated heparin [UFH]) • Famotidine • HMG-CoA reductase inhibitors (statins) • Immune globulin (IGIV, IVIG, γ-globulin) • Ivermectin • Nebulized drugs • Niclosamide • Nitazoxanide • Nonsteroidal anti-inflammatory agents (NSAIDs) • Tissue plasminogen activator (t-PA; alteplase) |